The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine

Molecular Pharmacology

Volumn 87, Issue 3, 2015, Pages 525-532

  Guerreiro, Serge ^a   Florence, Clélia ^a   Rousseau, Erwann ^a   Hamadat, Sabah ^a   Hirsch, Etienne C ^a   Michel, Patrick P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; GLIAL FIBRILLARY ACIDIC PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; MICROTUBULE ASSOCIATED PROTEIN 2; NICOTINE; NICOTINIC RECEPTOR; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN B; RECEPTOR SUBTYPE; RYANODINE RECEPTOR; VIMENTIN; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; OREXINS; SIGNAL PEPTIDE;

ACTIVE TRANSPORT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTROCYTE; CALCIUM CELL LEVEL; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; EMBRYO; ENDOPLASMIC RETICULUM; GLIA CELL; MESENCEPHALON; MODULATION; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; SLEEP; WISTAR RAT;

ANIMALS; CELLS, CULTURED; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCEPHALON; NERVE DEGENERATION; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NICOTINE; RATS; RATS, WISTAR; SLEEP;

EID: 84922163361     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095703     Document Type: Article

References (59)

1. Arnulf I (2012) REM sleep behavior disorder: motor manifestations and pathophysiology. Mov Disord 27:677-689.
2. Asahi S, Egashira S, Matsuda M, Iwaasa H, Kanatani A, Ohkubo M, Ihara M, and Morishima H (2003) Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg Med Chem Lett 13:111-113.
3. Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajos M, Higdon NR, Hoffmann WE, Hurst RS, and Myers JK et al. (2005) Discovery and structure-activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors. J Med Chem 48:905-908.
4. Boeve BF, Silber MH, Ferman TJ, Lucas JA, and Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16:622-630.
5. Boutrel B, Cannella N, and de Lecea L (2010) The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res 1314:103-111.
6. Calì T, Ottolini D, Negro A, and Brini M (2012) α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem 287:17914-17929.
7. Dauer W and Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909.
8. De Cock VC, Vidailhet M, and Arnulf I (2008) Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol 4:254-266.
9. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, and Bartlett FS, 2nd et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322-327.
10. Dickinson JA, Kew JN, and Wonnacott S (2008) Presynaptic α 7- and β 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 74:348-359.
11. Feng Y, Liu T, Li XQ, Liu Y, Zhu XY, Jankovic J, Pan TH, and Wu YC (2014) Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease. Neurosci Lett 579:35-40.
12. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, and Swaab DF (2007) Hypocretin (orexin) loss in Parkinson's disease. Brain 130:1577-1585.
13. Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, and Renger JJ (2012) Orexin receptors as therapeutic drug targets. Prog Brain Res 198:163-188.
14. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, and Michel PP (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74:980-989.
15. Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, and Arch JR (2002) Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 104:153-159.
16. He XB, Yi SH, Rhee YH, Kim H, Han YM, Lee SH, Lee H, Park CH, Lee YS, and Richardson E et al. (2011) Prolonged membrane depolarization enhances midbrain dopamine neuron differentiation via epigenetic histone modifications. Stem Cells 29:1861-1873.
17. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W (2007) Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun 354:707-711.
18. Hrabovszky E, Molnár CS, Borsay BÁ, Gergely P, Herczeg L, and Liposits Z (2013) Orexinergic input to dopaminergic neurons of the human ventral tegmental area. PLoS ONE 8:e83029.
19. Huang SC, Dai YW, Lee YH, Chiou LC, and Hwang LL (2010) Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors. J Pharmacol Exp Ther 334:522-529.
20. Ishibashi M, Takano S, Yanagida H, Takatsuna M, Nakajima K, Oomura Y, Wayner MJ, and Sasaki K (2005) Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides 26:471-481.
21. Karachi C, Grabli D, Bernard FA, Tandé D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker HP, and Hunot S et al. (2010) Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 120:2745-2754.
22. Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, and Randeva HS (2005) Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. Am J Physiol Endocrinol Metab 288:E1089-E1100.
23. Kaufman LM and Barrett JN (1983) Serum factor supporting long-term survival of rat central neurons in culture. Science 220:1394-1396.
24. 2+ transients mediated by L-type calcium channels. J Neurophysiol 100:2265-2281.
25. 2+) influx. Cell Calcium 30:117-129.
26. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, and Herdon HJ (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 141:340-346.
27. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, and Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376.
28. Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, and Moreau JL (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156:1326-1341.
29. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, and Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6-25.
30. Michel PP, Toulorge D, Guerreiro S, and Hirsch EC (2013) Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. FASEB J 27:3414-3423.
31. Mourlevat S, Troadec JD, Ruberg M, and Michel PP (2003) Prevention of dopaminergic neuronal death by cyclic AMP in mixed neuronal/glial mesencephalic cultures requires the repression of presumptive astrocytes. Mol Pharmacol 64:578-586.
32. Nakamura Y, Miura S, Yoshida T, Kim J, and Sasaki K (2010) Cytosolic calcium elevation induced by orexin/hypocretin in granule cell domain cells of the rat cochlear nucleus in vitro. Peptides 31:1579-1588.
33. Papke RL, Sanberg PR, and Shytle RD (2001) Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297:646-656.
34. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, and López-Barneo J (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11:755-761.
35. Perez-Leighton CE, Butterick-Peterson TA, Billington CJ, and Kotz CM (2013) Role of orexin receptors in obesity: from cellular to behavioral evidence. Int J Obes (Lond) 37:167-174.
36. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, and Albin R et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-997.
37. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, and Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015.
38. Postuma RB, Gagnon JF, and Montplaisir JY (2012) REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis 46:553-558.
39. Quik M, O'Neill M, and Perez XA (2007) Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28:229-235.
40. Rabenstein RL, Caldarone BJ, and Picciotto MR (2006) The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) 189:395-401.
41. 2+: molecular determinants and functional consequences. Physiol Rev 86:369-408.
42. Rousseau E, Michel PP, and Hirsch EC (2013) The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Mol Pharmacol 84:888-898.
43. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, and Wilson S et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
44. Salthun-Lassalle B, Hirsch EC, Wolfart J, Ruberg M, and Michel PP (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J Neurosci 24:5922-5930.
45. Salthun-Lassalle B, Traver S, Hirsch EC, and Michel PP (2005) Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. Mol Pharmacol 68:1214-1224.
46. Scammell TE and Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243-266.
47. Schulz JB (2007) Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat Disord 13 (Suppl 3):S306-S308.
48. Sokołowska P, Urbańska A, Biegańska K, Wagner W, Ciszewski W, Namiecińska M, and Zawilska JB (2014) Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci 52:48-55.
49. Spinazzi R, Ziolkowska A, Neri G, Nowak M, Rebuffat P, Nussdorfer GG, Andreis PG, and Malendowicz LK (2005) Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/p44- and p38-dependent cascades. Int J Mol Med 15:847-852.
50. Srinivasan R, Henderson BJ, Lester HA, and Richards CI (2014) Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease. Pharmacol Res 83:20-29.
51. Srinivasan R, Richards CI, Xiao C, Rhee D, Pantoja R, Dougherty DA, Miwa JM, Lester HA (2012) Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response. Mol Pharmacol 81:759-769.
52. Takai T, Takaya T, Nakano M, Akutsu H, Nakagawa A, Aimoto S, Nagai K, and Ikegami T (2006) Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor. J Pept Sci 12:443-454.
53. Thannickal TC, Lai YY, and Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130:1586-1595.
54. Tjondrokoesoemo A, Li N, Lin PH, Pan Z, Ferrante CJ, Shirokova N, Brotto M, Weisleder N, and Ma J (2013) Type 1 inositol (1,4,5)-trisphosphate receptor activates ryanodine receptor 1 to mediate calcium spark signaling in adult mammalian skeletal muscle. J Biol Chem 288:2103-2109.
55. 2+. FASEB J 25:2563-2573.
56. Traver S, Marien M, Martin E, Hirsch EC, and Michel PP (2006) The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 70:30-40.
57. Tsujino N and Sakurai T (2013) Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 7:28.
58. Zawilska JB, Urbańska A, and Sokołowska P (2013) Orexins/hypocretins stimulate accumulation of inositol phosphate in primary cultures of rat cortical neurons. Pharmacol Rep 65:513-516.
59. Ziolkowska A, Rucinski M, Tyczewska M, and Malendowicz LK (2008) Orexin B inhibits proliferation and stimulates specialized function of cultured rat calvarial osteoblast-like cells. Int J Mol Med 22:749-755.